Control of hyperuricemia in subjects with refractory gout, and induction of antibody against poly(ethylene glycol) (PEG), in a phase I trial of subcutaneous PEGylated urate oxidase

• Published in: Arthritis research & therapy Vol. 8; no. 1; p. R12
• Main Authors: Ganson, Nancy J, Kelly, Susan J, Scarlett, Edna, Sundy, John S, Hershfield, Michael S
• Format: Journal Article
• Language: English
• Published: England National Library of Medicine - MEDLINE Abstracts 01.01.2006; BioMed Central Ltd; BioMed Central
• Subjects: Adult; Aged; Carbon Radioisotopes; Female; Gout - complications; Gout - drug therapy; Humans; Hyperuricemia - prevention & control; Immunoglobulin G - therapeutic use; Male; Middle Aged; Polyethylene Glycols - toxicity; Recombinant Proteins - toxicity; Urate Oxidase - immunology; Urate Oxidase - pharmacokinetics; Urate Oxidase - toxicity; Urea - analogs & derivatives; Urea - metabolism; Uric Acid - metabolism

PEG-modified recombinant mammalian urate oxidase (PEG-uricase) is being developed as a treatment for patients with chronic gout who are intolerant of, or refractory to, available therapy for controlling hyperuricemia. In an open-label phase I trial, single subcutaneous injections of PEG-uricase (4 t...